Association between endostatin and mortality in patients with acute dyspnoea, with or without congestive heart failure: a single-centre, retrospective, observational study
Elevated endostatin levels independently predicted 3-month mortality in acute dyspnoeapatients with CHF, but not 1-month mortality. Endostatin may aid intermediate-term risk stratification and warrants further validation.
